Location：Home/News/Company NewsOriginal article by Yan Xiao | CPHI PharmaSources | March 12, 2025, 16:31, ShanghaiOn December 04, 2
Original article by Lao Yang666 | Talks on Pharmaceutical Chemistry January 01, 2025, 21:23, Shangha
According to the announcement of the National Healthcare Security Administration of China on Novembe
In March 2024, Kolupin? (Tunlametinib) was approved in China for use in patients with advanced NRAS-
The first worldwide MEK inhibitor approved for treating advanced NRAS-mutant melanoma.The first MEK
On January 23, 2024, Shanghai Kechow Pharma Inc. (“KeChow Pharma”) and Sinopharm Global Procurement
